Business
Q32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference
WALTHAM, Mass., April 8, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative
About this update from Q32 Bio Inc.
WALTHAM, Mass. , April 8, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) (" Q32 Bio "), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that management will participate in a fireside chat at 12:45 p.m. E.T. on Wednesday, April 15, 2026 at the 25th Annual Needham Virtual Healthcare Conference . A webcast of the presentation will be available on the Events and Presentations page of Q32 Bio's website at www.q32bio.com . An archived replay will be available for 90 days following the event. About Q32 Bio Q32 Bio is a clinical stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity and is focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases. About 700,000 people in the United States live with alopecia areata1, a disease which has a life-altering impact on patients and limited current treatment options. Q32 Bio is advancing bempikibart (ADX-914), a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases. For more information, visit www.Q32Bio.com . 1 National Alopecia Areata Foundation Availability of Other Information About Q32 Bio Investors and others should note that Q32 Bio communicates with its investors and the public using its website www.Q32Bio.com , including, but not limited to, Q32 Bio's disclosures, investor presentations and FAQs, Securities and Exchange Commission (the " SEC ") filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly Twitter) and LinkedIn. The information that Q32 Bio posts on its website or on X or LinkedIn could be deemed to be material information. As a result, Q32 Bio encourages investors, the media and others interested to review the information that it posts there on a regular basis. The contents of Q32 Bio's website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended. Contacts: Investors: Brendan Burns Argot Partners 212.600.1902 [email protected] Media: David Rosen Argot Partners 646.461.6387 [email protected] View original content to download multimedia: https://www.prnewswire.com/news-releases/q32-bio-to-participate-in-the-25th-annual-needham-virtual-healthcare-conference-302736130.html SOURCE Q32 Bio